IP Library Granted Patent US 7,368,446
Granted Patent B2
US 7,368,446 · App. 11/132,019 · Granted May 6, 2008

4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Assignee: Hoffmann-La Roche Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,368,446
App. No.
11/132,019
Granted
May 6, 2008
Kind
B2
Abstract

The present invention relates to the compound of formula which is 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compound is useful for the treatment or prevention of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD (attention deficit hyper-activity disorder), drug addiction to amphetamines, cocaine, opioids, ethanol, nicotine, or cannabinoids, or for the treatment of asthma, allergic responses, hypoxia, ischemia, seizure, substance abuse, or for use as muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents.

Claims (11)

1. The compound of formula

which is 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, or a pharmaceutically acceptable acid addition salt thereof.

2. A pharmaceutical composition comprising a compound of formula I

which is 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, or a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 2 , wherein the composition is in a form chosen from tablets, coated tablets, drages, hard gelatine capsules, soft gelatine capsules, solutions, emulsions, suspensions, suppositories, and injectable solutions.

4. The pharmaceutical composition of claim 2 , wherein the pharmaceutically acceptable excipient is chosen from pharmaceutically inert, inorganic or organic carriers.

5. The pharmaceutical composition of claim 4 , wherein the carrier is chosen from lactose, corn starch, talc, and stearic acids or its salts.

6. The pharmaceutical composition of claim 4 , wherein the carrier is chosen from vegetable oils, waxes, fats, semi-solid polyols, and liquid polyols.

7. The pharmaceutical composition of claim 4 , wherein the carrier is chosen from water, polyols, glycerol, and vegetable oil.

8. The pharmaceutical composition of claim 4 , wherein the carrier is chosen from natural or hardened oils, waxes, fats, semi-liquid polyols, and liquid polyols.

9. The pharmaceutical composition of claim 4 further comprising one or more preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents and antioxidants.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2006
From: FLOHR, ALEXANDER; MOREAU, JEAN-LUC; POLI, SONIA MARIA; RIEMER, CLAUS; STEWARD, LUCINDA
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 017613/0461 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2006
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 017607/0623 →
Priority Claims (1)
EP 04102262 · May 24, 2004 · regional
Continuity (1)
Related Publication 20050261289A1 · Nov 24, 2005